ANB101 — Initial data
2026
ANB101 (BDCA2 modulator): on track for Phase 1 results in 2026;Source filing
ANAB biotech catalysts & pipeline
ANAPTYSBIO INC · Data as of 2026-10-25
Upcoming catalysts
ANB033 — Topline data
Q4 2026
Top-line Phase 1b data for both cohorts anticipated in Q4 2026Source filing
imsidolimab (Quimilza) — Regulatory decision
Dec 2026
In addition to Jemperli , we anticipate FDA approval of Quimilza in GPP in December 2026.Source filing
imsidolimab (Quimilza) — PDUFA
Dec 12
FDA target action date (PDUFA) of Dec. 12, 2026, for Quimilza in generalized pustular psoriasis (GPP)Source filing
ANB033 — Topline data
2027
Top-line Phase 1b data anticipated in 2027Source filing
Jemperli (dostarlimab) — PDUFA
Feb 2027
Positive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA action date of February 2027 with eligibility for expedited review through the National Priority Voucher program, which could result in an earlier FDA decisionSource filing
Jemperli (dostarlimab) — Regulatory decision
Feb 2027
FDA PDUFA action date of February 2027 with eligibility for expedited review through the National Priority Voucher program, which could result in an earlier FDA decisionSource filing
Jemperli (dostarlimab) — Topline data
2028
Top-line data expected in 2028Source filing
Jemperli (dostarlimab) — Conference presentation
Oct 25
GSK to present first results from the AZUR-1 trial as a late-breaking abstract at ESMO Congress 2026 in Madrid, Spain on Oct. 25, 2026Source filing